158 related articles for article (PubMed ID: 37152483)
1. The 17-Gene Genomic Prostate Score Assay Is Prognostic for Biochemical Failure in Men With Localized Prostate Cancer After Radiation Therapy at a Community Cancer Center.
Canter DJ; Branch C; Shelnutt J; Foreman AJ; Lehman AM; Sama V; Edwards DK; Abran J
Adv Radiat Oncol; 2023; 8(4):101193. PubMed ID: 37152483
[TBL] [Abstract][Full Text] [Related]
2. The 17-Gene Genomic Prostate Score Test Is Prognostic for Outcomes After Primary External Beam Radiation Therapy in Men With Clinically Localized Prostate Cancer.
Janes JL; Boyer MJ; Bennett JP; Thomas VM; De Hoedt AM; Edwards V DK; Singla PK; Abran JM; Aboushwareb T; Salama JK; Freedland SJ
Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):120-131. PubMed ID: 36306979
[TBL] [Abstract][Full Text] [Related]
3. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
4. The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer.
Helfand BT; Paterakos M; Wang CH; Talaty P; Abran J; Bennett J; Hall DW; Lehman A; Aboushwareb T
PLoS One; 2022; 17(9):e0273782. PubMed ID: 36048818
[TBL] [Abstract][Full Text] [Related]
5. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.
Cullen J; Rosner IL; Brand TC; Zhang N; Tsiatis AC; Moncur J; Ali A; Chen Y; Knezevic D; Maddala T; Lawrence HJ; Febbo PG; Srivastava S; Sesterhenn IA; McLeod DG
Eur Urol; 2015 Jul; 68(1):123-31. PubMed ID: 25465337
[TBL] [Abstract][Full Text] [Related]
6. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
[TBL] [Abstract][Full Text] [Related]
7. Association Between Oncotype DX Genomic Prostate Score and Adverse Tumor Pathology After Radical Prostatectomy.
Covas Moschovas M; Chew C; Bhat S; Sandri M; Rogers T; Dell'Oglio P; Roof S; Reddy S; Sighinolfi MC; Rocco B; Patel V
Eur Urol Focus; 2022 Mar; 8(2):418-424. PubMed ID: 33757735
[TBL] [Abstract][Full Text] [Related]
8. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
9. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System.
Yamoah K; Lee KM; Awasthi S; Alba PR; Perez C; Anglin-Foote TR; Robison B; Gao A; DuVall SL; Katsoulakis E; Wong YN; Markt SC; Rose BS; Burri R; Wang C; Aboiralor O; Fink AK; Nickols NG; Lynch JA; Garraway IP
JAMA Netw Open; 2022 Jan; 5(1):e2144027. PubMed ID: 35040965
[TBL] [Abstract][Full Text] [Related]
10. GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer-Specific Mortality.
Brooks MA; Thomas L; Magi-Galluzzi C; Li J; Crager MR; Lu R; Abran J; Aboushwareb T; Klein EA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036236
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of 17-Gene genomic prostate score in patients with clinically localized prostate cancer: a meta-analysis.
Cui F; Tang X; Man C; Fan Y
BMC Cancer; 2024 May; 24(1):628. PubMed ID: 38783246
[TBL] [Abstract][Full Text] [Related]
12. Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN).
Ma TM; Chu FI; Sandler H; Feng FY; Efstathiou JA; Jones CU; Roach M; Rosenthal SA; Pisansky T; Michalski JM; Bolla M; de Reijke TM; Maingon P; Neven A; Denham J; Steigler A; Joseph D; Nabid A; Souhami L; Carrier N; Incrocci L; Heemsbergen W; Pos FJ; Sydes MR; Dearnaley DP; Tree AC; Syndikus I; Hall E; Cruickshank C; Malone S; Roy S; Sun Y; Zaorsky NG; Nickols NG; Reiter RE; Rettig MB; Steinberg ML; Reddy VK; Xiang M; Romero T; Spratt DE; Kishan AU;
Eur Urol; 2022 Nov; 82(5):487-498. PubMed ID: 35934601
[TBL] [Abstract][Full Text] [Related]
13. The 17-Gene Genomic Prostate Score Test as a Predictor of Outcomes in Men with Unfavorable Intermediate Risk Prostate Cancer.
Cullen J; Kuo HC; Shan J; Lu R; Aboushwareb T; Van Den Eeden SK
Urology; 2020 Sep; 143():103-111. PubMed ID: 32525077
[TBL] [Abstract][Full Text] [Related]
14. Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer.
Wang LS; Murphy CT; Ruth K; Zaorsky NG; Smaldone MC; Sobczak ML; Kutikov A; Viterbo R; Horwitz EM
Cancer; 2015 Sep; 121(17):3010-7. PubMed ID: 26033633
[TBL] [Abstract][Full Text] [Related]
15. Validation of the Combination Gleason Score as an Independent Favorable Prognostic Factor in Prostate Cancer Treated With Dose-Escalated Radiation Therapy.
Quinn TJ; Chapman D; Parzen J; Wahl DR; McNamara A; Dess R; Chan J; Feng F; Jackson WC; Hamstra D
Pract Radiat Oncol; 2023; 13(2):e166-e175. PubMed ID: 36503624
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Eur Urol; 2014 Jan; 65(1):177-85. PubMed ID: 22981136
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
Voog JC; Paulus R; Shipley WU; Smith MR; McGowan DG; Jones CU; Bahary JP; Zeitzer KL; Souhami L; Leibenhaut MH; Rotman M; Husain SM; Gore E; Raben A; Chafe S; Sandler HM; Efstathiou JA
Eur Urol; 2016 Feb; 69(2):204-10. PubMed ID: 26362090
[TBL] [Abstract][Full Text] [Related]
18. 17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort.
Lin DW; Zheng Y; McKenney JK; Brown MD; Lu R; Crager M; Boyer H; Tretiakova M; Brooks JD; Dash A; Fabrizio MD; Gleave ME; Kolb S; Liss M; Morgan TM; Thompson IM; Wagner AA; Tsiatis A; Pingitore A; Nelson PS; Newcomb LF
J Clin Oncol; 2020 May; 38(14):1549-1557. PubMed ID: 32130059
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Factors for Prostate Cancer Endpoints Following Biochemical Failure: A Review of the Literature.
Nguyen T; Boldt RG; Rodrigues G
Cureus; 2015 Jan; 7(1):e238. PubMed ID: 26180662
[TBL] [Abstract][Full Text] [Related]
20. Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials.
Kishan AU; Chu FI; King CR; Seiferheld W; Spratt DE; Tran P; Wang X; Pugh SE; Sandler KA; Bolla M; Maingon P; De Reijke T; Nickols NG; Rettig M; Drakaki A; Liu ST; Reiter RE; Chang AJ; Feng FY; Sajed D; Nguyen PL; Kupelian PA; Steinberg ML; Boutros PC; Elashoff D; Collette L; Sandler HM
Eur Urol; 2020 Feb; 77(2):201-208. PubMed ID: 31718822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
